GHRS.US GH Research PLC

Healthcare Biotechnology USA Stocks
19.10 USD
Close of Nov 14, 2026
12.04 31.44
Market cap
USD 1.31B
P/E
-
P/B
3.53x
ROE
-19.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GHRS.US undervalued?

Graham number

The Graham number of GH Research PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GH Research PLC fundamental analysis

No fundamental analysis for GH Research PLC yet.

GH Research PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GH Research PLC

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebu…

Full company profile